美股A股
StockGist
Back
8-K2026-03-20· x-ai/grok-4.1-fast

ANTX · AN2 Therapeutics, Inc.

0001193125-26-117765

SEC filing

Summary

On March 19, 2026, the Board of AN2 Therapeutics, Inc. approved a stock option repricing of all outstanding Eligible Options under the 2017 and 2022 Equity Incentive Plans to $3.91 per share, including options held by named executive officers and non-employee directors. This provides retention incentives without stock dilution or additional cash costs.

Key takeaways